Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 8 trials

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (3)
P 3 (1)

Trial Status

Recruiting3
Enrolling By Invitation1
Active Not Recruiting1
Unknown1
Withdrawn1
Not Yet Recruiting1

Clinical Trials (8)

Showing 8 of 8 trials
NCT04084067Phase 1RecruitingPrimary

Indocyanine Green (ICG) Guided Tumor Resection

NCT07100730Phase 3RecruitingPrimary

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

NCT05450744Phase 1RecruitingPrimary

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

NCT02159742Active Not RecruitingPrimary

Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases

NCT06825429Not ApplicableNot Yet RecruitingPrimary

Group Exercise in Cancer Patients Under Active Treatment: Feasibility Pilot Study.

NCT03197363Enrolling By Invitation

Białystok PLUS - Polish Longitudinal University Study

NCT02582827Phase 1WithdrawnPrimary

QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

NCT02786199UnknownPrimary

Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging

Showing all 8 trials

Research Network

Activity Timeline